CD8+ or CD103+ DCs are known to be particularly effective at crosspriming, and two recent papers report that the presence of CD103+ DCs in tumors correlates with spontaneous tumor rejection (4) and response to treatment with paclitaxel in combination with CSF1 blockade (21). The gene discussed is CSF1; the disease is neoplasm.